Regulation of blood-retina barrier by placental growth factor

胎盘生长因子对血视网膜屏障的调节

基本信息

批准号：
10684755
负责人：
Hu Huang
金额：
$ 42.74万
依托单位：
UNIVERSITY OF MISSOURI-COLUMBIA
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-04-01 至 2027-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10684755
关键词：
Address Antioxidants Apoptosis Apoptotic Area Automobile Driving Belief Blindness Blood-Retinal Barrier Breeding CRISPR/Cas technology Cell Culture Techniques Cell Survival Cells Cessation of life Clinical Complications of Diabetes Mellitus Development Diabetes Mellitus Diabetic Retinopathy Diabetic mouse Endothelial Cells Erythrocytes Eye FOXO1A gene Functional disorder Gene Expression Profile Gene Silencing Gene Transfer Genetic Models Glucose Glucosephosphate Dehydrogenase Glucosephosphate Dehydrogenase Deficiency Glycolysis Goals HDAC9 gene Homeostasis Human Impairment In Vitro Intervention Knock-out Knockout Mice Knowledge Label Lentivirus Ligands LoxP-flanked allele MAP Kinase Gene Measurement Measures Mediating Metabolic Mitochondria Mononuclear Muller&apos s cell Mus NADP Natural regeneration Neurons Outcome Oxidation-Reduction Oxidative Stress Oxidative Stress Induction Oxygen Consumption PGF gene PI3K/AKT Pathogenesis Pathology Pentosephosphate Pathway Pharmacologic Substance Phenotype Phosphotransferases Play Predisposition Reaction Reduced Glutathione Regulation Reporting Research Retina Rod Role STAT1 gene Signal Pathway Signal Transduction Stable Isotope Labeling Streptozocin Stress System Testing Tissues Tracer Transfection VEGFA gene Vascular Endothelial Growth Factor Receptor-1 Virulence Factors Virus Vision antioxidant enzyme conditional knockout dehydroepiandrosterone design diabetic experimental study expression vector extracellular gain of function genome editing glucose metabolism in vivo innovation insight kidney cell knock-down liquid chromatography mass spectrometry macular edema metabolomics mitochondrial dysfunction mouse model novel novel strategies overexpression oxidative damage prevent protective effect protective pathway receptor retinal damage retinal rods small hairpin RNA small molecule stem cells transcription factor translational potential vector

项目摘要

Project Abstract Diabetic retinopathy (DR) is a common complication of diabetes causing vision loss. Diabetes- induced metabolic abnormality and mitochondrial dysfunction resulting in oxidative stress is a primary pathogenic factor driving DR onset and development. This proposal will complete the two Aims: (1) To elucidate how placental growth factor (PlGF) mediates DR-related pathology by suppressing glucose 6 phosphate dehydrogenase (G6PD) activity and oxidative pentose phosphate pathway (oxPPP) flux. (2) To determine the protective role of G6PD’s antioxidant function via oxPPP in retinal cells against diabetes- induced oxidative injury. More specifically, the PlGF signaling pathway molecules involved in regulating G6PD expression and activity will be uncovered. The new mechanisms by which PlGF mediates diabetes- induced retinal endothelial cell barrier dysfunction and other DR-related pathologies through the metabolic shift from PPP to glycolysis and mitochondrial dysfunction will be elucidated in cell cultures and murine models. G6PD’s protective role in DR will be determined using cell-/tissue-specific G6PD conditional knockout (cKO) and conditional overexpression (cOE) mice, as well as AAV-based G6PD expression vector and small-molecule G6PD activator. Overall, the research is designed to elucidate the regulation and role of the “diabetes-PlGF-G6PD-oxidative stress” signaling cascades in DR pathogenesis. The outcomes will give mechanistic insight into DR pathogenesis in general and PlGF function in particular. Since that PlGF has emerged as a promising target molecule to treat DR and diabetic macular edema (DEM), understanding the underlying mechanism is significant. Given the central role of G6PD-gated oxPPP in regulating redox homeostasis and cell survival under stress conditions, this project will fill a critical knowledge gap regarding whether G6PD’s antioxidant function via oxPPP plays a pivotal role in protecting retinal cells from diabetes-induced oxidative damage and compromised G6PD activity and limited oxPPP flux contribute to DR pathogenesis. To examine metabolic flux and mitochondrial function, quantitative measurements will be applied, including stable labeling tracer [1,2-13C2]glucose, liquid chromatography/mass spectrometry, targeted metabolomics, oxygen consumption rate/extracellular acidification rate. Cutting-edge approaches will be employed to determine G6PD’s protective effect, such as gene silence (shRNA), genetic models (cKO and cOE mouse), CRISPR-Cas9 genome editing, virus- based gene transfer, and pharmaceutical compounds. In summary, this project is innovative because it will elucidate a novel mechanism for PlGF to mediate DR-related pathology by regulating glucose metabolism and provide new insights into the question(s) “why or how are retinal cells become vulnerable to diabetes-induced oxidative stress?”. It will also explore the new approaches to prevent or delay DR and DME development by enhancing antioxidant capacity.

项目摘要糖尿病视网膜病变（DR）是导致视力丧失的糖尿病常见并发症。诱导的代谢异常和线粒体功能障碍导致氧化应激是主要的该提案将完成两个目标：（1）阐明胎盘生长因子 (PlGF) 如何通过抑制葡萄糖来介导 DR 相关病理学 6 磷酸脱氢酶 (G6PD) 活性和氧化戊糖磷酸途径 (oxPPP) 通量 (2) To。确定 G6PD 的抗氧化功能通过 oxPPP 在视网膜细胞中对抗糖尿病的保护作用更具体地说，PlGF信号通路分子参与调节。 G6PD 表达和活性将被揭示 PlGF 介导糖尿病的新机制。通过代谢诱导视网膜内皮细胞屏障功能障碍和其他 DR 相关病理从 PPP 到糖酵解的转变和线粒体功能障碍将在细胞培养物和小鼠中得到阐明 G6PD 在 DR 中的保护作用将使用细胞/组织特异性 G6PD 条件来确定。敲除 (cKO) 和条件过表达 (cOE) 小鼠，以及基于 AAV 的 G6PD 表达总体而言，该研究旨在阐明调控。以及“糖尿病-PlGF-G6PD-氧化应激”信号级联在 DR 发病机制中的作用。结果将有助于深入了解 DR 发病机制，特别是 PlGF 功能。自那以后，PlGF 已成为治疗 DR 和糖尿病性黄斑水肿的有前途的靶分子 (DEM)，鉴于 G6PD 门控的核心作用，了解其基本机制具有重要意义。 oxPPP 在调节应激条件下的氧化还原稳态和细胞存活方面，该项目将填补关于 G6PD 通过 oxPPP 的抗氧化功能是否在保护视网膜细胞免受糖尿病引起的氧化损伤和 G6PD 活性受损，有限的 oxPPP 通量有助于 DR 发病机制为了检查代谢通量和线粒体功能，将应用定量测量，包括稳定的标记示踪剂[1,2-13C2]葡萄糖，液体色谱/质谱、靶向代谢组学、耗氧率/细胞外将采用尖端方法来确定 G6PD 的保护作用，例如如基因沉默（shRNA）、遗传模型（cKO 和 coE 小鼠）、CRISPR-Cas9 基因组编辑、病毒- 总而言之，这个项目是创新的，因为它。将阐明 PlGF 通过调节葡萄糖介导 DR 相关病理的新机制新陈代谢，并为“视网膜细胞为何或如何变得脆弱”这一问题提供新的见解它还将探索预防或延迟 DR 和糖尿病引起的氧化应激的新方法。通过增强抗氧化能力开发DME。